MUSTAFA SIDALI: Open Payments
NPI 1811982762 · BELLEVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,740 in 84 payments from 17 companies in 2025. Trend: 2023 $137 · 2024 $1,818 · 2025 $1,740
Food & beverage: $1,655Education: $85
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $331 |
| AstraZeneca Pharmaceuticals LP | 15 | $314 |
| GlaxoSmithKline, LLC. | 6 | $201 |
| Mannkind Corporation | 11 | $172 |
| Lilly USA, LLC | 11 | $164 |
| Madrigal Pharmaceuticals | 1 | $148 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $69 |
| Kowa Pharmaceuticals America, Inc. | 4 | $57 |
| Exact Sciences Corporation | 2 | $50 |
| ABBVIE INC. | 3 | $48 |
Products named: Ozempic, FARXIGA, AFREZZA, REZDIFFRA, MOUNJARO, AREXVY, JARDIANCE, BREZTRI.
Industry payments across NJ — which companies pay providers there.
